logo
Menu

We provide briefings on technologies to different public stakeholders, from those delivering care and research funders stimulating innovation, to policy makers and advisory bodies. Most, if not all of these briefings, will be publicly available on this website via the search window.

Innovation Observatory > Reports > Drugs > Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

< Back

Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm

Drugs

Cancer and Palliative Care

September 2018


Tagraxofusp is being investigated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). Previously known as natural killer (NK) cell leukaemia/lymphoma, BPDCN
was categorized by the World Health Organization under acute myeloid leukaemia (AML) but now has its own separate designation under myeloid neoplasms. BPDCN is a rare blood
cancer derived from the precursors of cells called plasmacytoid dendritic cells.
Tagraxofusp is a fusion protein formed by combining interleukin‐3 (IL‐3) and truncated diphtheria toxin (DT). It causes inactivation of protein synthesis, and death of the target cell.
Treatment for BPDCN has included therapies that are used for AML, acute lymphoblastic leukaemia (ALL), or lymphoma. If licensed, tagraxofusp will offer the first prospectively
studied treatment option for BPDCN for which there are limited treatment options and a significant unmet medical need.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts